Safety and Drug Levels of Combined Insulin Degludec/Liraglutide Investigated in Healthy Subjects
Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects
Background
Insulin Degludec is a novel, ultra-long-acting basal insulin analog, providing glucose-lowering effects for over 42 hours, while Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion and suppresses glucagon. Both are critical treatments for managing type 2 diabetes, a chronic metabolic disorder characterized by high blood sugar. The development of a fixed-ratio combination, Insulin Degludec/Liraglutide (A3), aimed to simplify daily injections for patients. However, before clinical use, it was paramount to thoroughly assess the pharmacokinetic interactions, safety, and tolerability of this combined formulation compared to its individual components in healthy individuals.
Study Design
Population
Healthy subjects were studied to assess the combined formulation of Insulin Degludec/Liraglutide.
Intervention
The combined formulation of Insulin Degludec/Liraglutide (A3) was administered.
Comparator
Individual components of Insulin Degludec and Liraglutide were used as comparators.
Outcome
The primary outcomes measured were pharmacokinetic interactions, safety, and tolerability of the combined formulation.